Laquinimod treatment in the R6/2 mouse model-Reference-Cited by-同舟云学术

Laquinimod treatment in the R6/2 mouse model

Published:2017-07-10 Issue:1 Volume:7 Page:
ISSN:2045-2322
Container-title:Scientific Reports
language:en
Short-container-title:Sci Rep

Author:

Ellrichmann Gisa,Blusch Alina,Fatoba Oluwaseun,Brunner Janine,Reick Christiane,Hayardeny Liat,Hayden Michael,Sehr Dominik,Winklhofer Konstanze F.,Saft Carsten,Gold Ralf

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/s41598-017-04990-1.pdf

Reference69 articles.

1. Vonsattel, J. P. & DiFiglia, M. Huntington disease. Journal of neuropathology and experimental neurology 57, 369–384 (1998).

2. Reddy, P. H. et al. Transgenic mice expressing mutated full-length HD cDNA: a paradigm for locomotor changes and selective neuronal loss in Huntington’s disease. Philosophical transactions of the Royal Society of London. Series B, Biological sciences 354, 1035–1045, https://doi.org/10.1098/rstb.1999.0456 (1999).

3. Reiner, A. et al. Differential loss of striatal projection neurons in Huntington disease. Proceedings of the National Academy of Sciences of the United States of America 85, 5733–5737 (1988).

4. Bossy-Wetzel, E., Petrilli, A. & Knott, A. B. Mutant huntingtin and mitochondrial dysfunction. Trends in neurosciences 31, 609–616, https://doi.org/10.1016/j.tins.2008.09.004 (2008).

5. Kumar, P., Kalonia, H. & Kumar, A. Huntington’s disease: pathogenesis to animal models. Pharmacological reports: PR 62, 1–14 (2010).

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Emerging pharmacological approaches for Huntington's disease;European Journal of Pharmacology;2024-10

2. Huntington’s Disease: Latest Frontiers in Therapeutics;Current Neurology and Neuroscience Reports;2024-06-11

3. Рroblems of diagnostics of dysfunctions of the olfactory analyzer of laboratory animals on the basis of behavioral and electrophysiological methods of research;Сенсорные системы;2024-05-21

4. Inflammation and Huntington’s disease – a neglected therapeutic target?;Expert Opinion on Investigational Drugs;2024-05-03

5. Efficacy of therapy by MK-28 PERK activation in the Huntington's disease R6/2 mouse model;Neurotherapeutics;2024-03